ROS formation, suppression of anti-apoptotic proteins Bcl-XL and Mcl-1, increased Beclin 1 and ATG5 levels, and promotion of autophagosome formation were discovered in BRAFV600E patient-derived xenograft (PDX) melanoma cells treated with the ERBB and MAPK4 inhibitor neratinib, and synergy effects were observed in combination with HDAC inhibitors[101]. This evidence concerns the gene BCL2L1 and melanoma.